Ajinomoto Co., Inc. launched a new version of its StemFit iPSC expansion medium. The enhanced version of its widely used StemFit products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API). While iPSCs are used for developing and discovering cellular medicines that have the potential to change the way doctors treat intractable diseases, StemFit ensures high survival rates and rapid proliferation of cells, reducing both the time and cost of generating iPSCs.

Its animal- origin-free formulation reduces spontaneous differentiation, enabling efficient single-cell passing. The product line-up of StemFit is ideal for regenerative medicine, drug discovery and disease modeling. Additionally, it also enhances further manufacturing of cellular medicines, ensuring superior performance and reliability in iPSC culture.

The Ajinomoto Group recently enhanced its product manufacturing and quality control methods for cell therapy developers to use StemFit as a raw material for iPSC cellular medicine by leveraging the Ajinomoto Group's facilities and capabilities in manufacturing Good Manufacturing Practice (GMP). This enhancement not only allows the ability to produce high-quality, reliable products but also ensures strict quality control at each stage of the manufacturing process. The Group's expertise in GMP API production contributes to the superior performance of the StemFit medium, ensuring it meets the industry standards.